New dual immunotherapy aims to stop liver cancer recurrence after surgery
NCT ID NCT07658105
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase 2 trial tests whether eparlitozoviril, a dual immunotherapy drug, can prevent liver cancer from returning after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug or active surveillance. The main goal is to see how many remain cancer-free after one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eparlitozoviril (a dual immunotherapy drug targeting PD-1 and CTLA-4)
What this could lead to
If successful, this could provide a new option to lower the chance of liver cancer returning after surgery for patients with microvascular invasion.
What could go wrong
This is a small, early-phase study (60 people) at one center, so results may not apply broadly. Immunotherapy can cause serious side effects like immune system overactivation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.